Key result
Good adherence to HFrEF guidelines significantly reduced the 60-day composite endpoint of mortality and heart failure rehospitalization (wHR 0.47) compared to poor adherence in patients with HFpEF and atrial fibrillation.
Why the study?
To evaluate the relationship between guideline adherence for HFrEF at discharge and clinical outcomes in patients with acute HFpEF with or without AF.
Does good adherence to HFrEF guideline-directed medical therapy improve clinical outcomes in patients with HFpEF with or without atrial fibrillation?
Cohort (n=1,394)
Yes
Does good adherence to HFrEF guideline-directed medical therapy improve clinical outcomes in patients with HFpEF with or without atrial fibrillation?
Effect estimate: wHR 0.47 (95% CI 0.27-0.79)
Absolute Event Rate: 7.7% vs 15.9%
p-value: p=0.005
Good adherence to HFrEF guideline-directed medical therapy is associated with improved 60-day clinical outcomes in HFpEF patients with atrial fibrillation, but not in those with normal sinus rhythm.
Background: This study evaluated the relationship between guideline adherence for heart failure (HF) with reduced ejection fraction (HFrEF) at discharge and relevant clinical outcomes in patients with acute HF with preserved ejection fraction (HFpEF) with or without atrial fibrillation (AF). Methods: We analyzed Korean Acute Heart Failure Registry data for 707 patients with HFpEF with documented AF and 687 without AF. Guideline adherence was defined as good or poor according to the prescription of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, -blockers, and mineralocorticoid receptor antagonists. Anticoagulation adherence was also incorporated for the AF group. Results: Among patients with normal sinus rhythm, those with poor guideline adherence had a reduced prevalence of comorbidities and favorable clinical characteristics when compared with those with good guideline adherence. Using inverse probability of treatment weighting (IPTW) to address the bias of nonrandom treatment assignment, good adherence was associated with a poor 60-day composite endpoint in the multivariable Cox model (weighted hazard ratio [wHR], 1.74; 95% confidence interval [CI], 1.01-3.00; P = 0.045). For patients with AF, baseline clinical characteristics were similar according to the degree of adherence. The IPTW-adjusted analysis indicated that good adherence was significantly associated with the 60-day composite endpoint (wHR, 0.47; 95% CI, 0.27-0.79; P = 0.005). In the analysis excluding warfarin, good adherence was associated with 60-day rehospitalization (wHR, 0.60; 95% CI, 0.37-0.98; P = 0.040), 1-year re-hospitalization (wHR, 0.67; 95% CI, 0.48-0.93; P = 0.018), and the composite endpoint (wHR, 0.77; 95% CI, 0.59-0.99; P = 0.041).
No takes yet. Share an insight, caveat, or question.
Ahn et al. (2021) conducted a cohort in Heart failure with preserved ejection fraction (HFpEF) with or without atrial fibrillation (n=1,394). Good guideline adherence vs. Poor guideline adherence was evaluated on 60-day composite endpoint of mortality and heart failure rehospitalization in patients with atrial fibrillation (wHR 0.47, 95% CI 0.27-0.79, p=0.005). Good adherence to HFrEF guidelines significantly reduced the 60-day composite endpoint of mortality and heart failure rehospitalization (wHR 0.47) compared to poor adherence in patients with HFpEF and atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: